Chemoinformaics analysis of (-)-Neoclovene-(I), dihydro-
| Molecular Weight | 206.373 | nRot | 0 |
| Heavy Atom Molecular Weight | 180.165 | nRig | 13 |
| Exact Molecular Weight | 206.203 | nRing | 3 |
| Solubility: LogS | -6.316 | nHRing | 0 |
| Solubility: LogP | 5.315 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 3 |
| Atoms Count | 41 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 0 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 4 | No. Saturated Carbocycles | 3 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 42.3866 |
| nHD | 0 | BPOL | 26.0834 |
| QED | 0.547 |
| Synth | 5.052 |
| Natural Product Likeliness | 2.812 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.058 |
| Pgp-sub | 0 |
| HIA | 0.004 |
| CACO-2 | -4.724 |
| MDCK | 0.0000106 |
| BBB | 0.862 |
| PPB | 0.969444 |
| VDSS | 2.177 |
| FU | 0.0365191 |
| CYP1A2-inh | 0.239 |
| CYP1A2-sub | 0.732 |
| CYP2c19-inh | 0.288 |
| CYP2c19-sub | 0.934 |
| CYP2c9-inh | 0.348 |
| CYP2c9-sub | 0.614 |
| CYP2d6-inh | 0.029 |
| CYP2d6-sub | 0.641 |
| CYP3a4-inh | 0.193 |
| CYP3a4-sub | 0.352 |
| CL | 15.803 |
| T12 | 0.076 |
| hERG | 0.021 |
| Ames | 0.013 |
| ROA | 0.063 |
| SkinSen | 0.36 |
| Carcinogencity | 0.024 |
| EI | 0.332 |
| Respiratory | 0.798 |
| NR-Aromatase | 0.007 |
| Antiviral | Yes |
| Prediction | 0.933264 |